Workflow
Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study
Globenewswireยท2025-07-08 21:10

Core Viewpoint - Revive Therapeutics Ltd. is conducting a research study on Bucillamine as a potential treatment for nerve agent exposure in collaboration with Defence R&D Canada [1][2] Group 1: Research Study Details - The research study on Bucillamine is set to continue through September 2025, with findings to be shared only with DRDC's authorization [2] - Future research collaborations with DRDC will only be considered after the current study concludes and if results are satisfactory [2] Group 2: Company Overview - Revive Therapeutics focuses on developing therapeutics for infectious diseases and medical countermeasures, leveraging FDA regulatory incentives like Emergency Use Authorization and Breakthrough Therapy designations [3] - The company is also exploring Bucillamine for long COVID treatment and advancing Psilocybin and molecular hydrogen therapeutics [3]